Indivisible Partners Purchases Shares of 16,458 Cencora, Inc. $COR

Indivisible Partners purchased a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,458 shares of the company’s stock, valued at approximately $5,559,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Stevens Capital Management LP acquired a new stake in Cencora in the fourth quarter valued at $671,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Cencora by 5.2% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 400,605 shares of the company’s stock valued at $135,753,000 after buying an additional 19,801 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in Cencora by 44.7% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 24,468 shares of the company’s stock valued at $8,264,000 after buying an additional 7,557 shares in the last quarter. Highland Capital Management LLC acquired a new stake in Cencora in the fourth quarter valued at $2,348,000. Finally, Principal Financial Group Inc. raised its stake in Cencora by 1.9% in the fourth quarter. Principal Financial Group Inc. now owns 252,956 shares of the company’s stock valued at $85,436,000 after buying an additional 4,794 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wells Fargo & Company raised their price target on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. William Blair assumed coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, JPMorgan Chase & Co. lifted their target price on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $398.17.

Cencora Stock Up 0.7%

COR opened at $305.89 on Wednesday. The business’s 50-day simple moving average is $332.27 and its 200-day simple moving average is $343.21. The stock has a market capitalization of $59.50 billion, a P/E ratio of 36.77, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. Cencora, Inc. has a one year low of $271.00 and a one year high of $377.54. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.80 by ($0.05). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts anticipate that Cencora, Inc. will post 17.58 EPS for the current year.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.